展品99.1

​

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

​

-- Achieved $12820万 in AYVAKIT 2024年第三季度净产品收入区间

调升2024年AYVAKIt净产品收入指引至47500万至48000万美元

预计按计划在年底前启动elenestinib在ISm中注册启动的HARBOR Part 2研究

​

​

2024年10月30日麻省剑桥─ Blueprint Medicines Corporation（纳斯达克代码：BPMC）今天报告了财务业绩，提供了截至2024年9月30日第三季度的业务更新，并提供了最新的财务指引。

​

“通过另一个强劲的AYVAKIt营收业绩季度，我们截至目前的业绩为我们在2025年及未来实现显著增长和创造长期股东价值奠定了基础。AYVAKIt的业绩增长势头使我们有信心再次提高我们今年的营收预期，估计我们将以47500万至48000万美元的收入结束本年度。在接近五亿美元的营收下，结束我们首个完整年度的推出，使AYVAKIt得以成为迄今为止最成功的罕见疾病推广之一，” Blueprint Medicines的执行长凯特·哈维兰说。“AYVAKIt已经在全球病人中显示出了具体好处，长期数据进一步强化了临床上具有意义的好处和耐受性良好的疾病修改治疗的轮廓。AYVAKIt的强劲营收增长加上对最具说服力的产品机会的纪律性投资，使蓝图药物处于实现今年现金燃烧显著下降的位置，同时保持我们专注于长期增长和价值创造。”

​

2024年第三季度亮点和最近进展

​

肥大细胞疾病

​

​

2024年财务展望

​

Blueprint Medicines now anticipates approximately $47500万 to $48000万 in global AYVAKIt net product revenues in 2024, an increase from the previous range of $43500万 to $45000万. This updated guidance is based on continued growth in patients on therapy, continued favorability in compliance and other performance factors, and stronger than expected performance outside of the U.S. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023, and that its existing cash, cash equivalents and investments, together with anticipated product revenues, will enable the company to maintain a

稳固的资本位置，以实现自给自足的财务状况。

​

重要即将达成的里程碑

​

该公司计划在2024年底前实现以下剩余里程碑：

​

肥大细胞疾病

​

细胞周期抑制

​

2024年第三季度成果

​

​

会议看涨信息

​

Blueprint Medicines将于今天上午8:00举行现场电话会议和网络直播，以讨论2024年第三季度的财务业绩和最近的业务活动。可以通过拨打833-470-1428（国内）或404-975-4839（国际），并参考会议ID 387547来参加电话会议。电话会议的网络直播也将在Blueprint Medicines网站的“投资者及媒体”部分的“活动和演示文稿”下提供。http://ir.blueprintmedicines.com/蓝图药物的网络研讨会存档将在会后大约两个小时发布在蓝图药物的网站，并在通话后的30天内提供。

​

即将举行的投资者会议

​

蓝图药物将参加三场即将举行的投资者会议：

​

Scientific Webinar Series

​

​

A live webcast of the above presentations and any related slides will be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on the Blueprint Medicines website following the events.

​

About Blueprint Medicines

​

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

​

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines’ operations, including its expectations regarding growth and net product revenue in 2024; statements regarding its current or future approved drugs and drug candidates and operations, including plans to initiate registration-enabling Part 2 of the HARBOR trial of elenestinib in ISM in 2024, complete Phase 1 combination dose escalation for BLU-222 to inform registration plans and continue strategic business development discussions by the end of 2024, and present healthy volunteer data from its Phase 1 trial for BLU-808 in early 2025; expectations related to the markets for current or future approved drugs and drug candidates, including expectations regarding the size or scale of patient opportunities that future approved drugs and drug candidates could address; the potential benefits of any of its current or future approved drugs or drug candidates in treating patients; statements related to liquidity and capital position, including expectations that its cash, cash equivalents and investments will provide a durable capital position which, together with anticipated product revenues, will enable Blueprint Medicines to reach a self-sustainable financial profile; and its financial performance, strategy, goals and anticipated milestones, business plans and focus, including expectations regarding its revenue ramp and continued decline in operating expenses and cash burn. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the risk that the marketing and sale of AYVAKIT/AYVAKYT or any future approved drugs may be unsuccessful or less successful than anticipated, or that AYVAKIT/AYVAKYT may not gain market acceptance by physicians, patients, third-party payors and others in the medical community; the risk that the market opportunities for AYVAKIT/AYVAKYT or Blueprint Medicines’ drug candidates are smaller than we estimate or that any approval we obtain may be based on a narrower definition of the patient population that we anticipate; the risk of delay of any current or planned clinical trials or the development of Blueprint Medicines’ current or future

drug candidates; risks related to Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results for Blueprint Medicines' drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; actions of regulatory agencies may affect its approved drugs or its current or future drug candidates, including affecting the initiation, timing and progress of clinical trials; risks related to Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing and other arrangements; risks related to its liquidity and financial position, including the risk that Blueprint Medicines may be unable to generate sufficient future product revenues to achieve and maintain a self-sustainable financial profile; and the accuracy of its estimates of revenues, expenses and capital requirements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

​

​

Trademarks

​

Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.

​

​

Blueprint Medicines Corporation

Selected Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

​

(1)   Blueprint Medicines defines working capital as current assets less current liabilities.

​

​

Blueprint Medicines Corporation

Condensed Consolidated Statements of Operations Data

(in thousands, except per share data)

(unaudited)

​

​

Media Contact 

Andrew Law

617-844-8205

media@blueprintmedicines.com

Investor Contact 

Jenna Cohen

857-209-3147

ir@blueprintmedicines.com